Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.38 |
| ▸ | CKS1B | P61024 | 2/20 | 0.38 |
| ▸ | SKP1 | P63208 | 2/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KAT7 | O95251 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494568 | 0.91 | KMT2A (0.35) | — | |
| SCHEMBL13340903 | 0.86 | CKS1B (0.38) | CKS1BSKP1SKP2PARP1ABHD6 | |
| SCHEMBL8229917 | 0.86 | NR1H2 (0.57) | NR1H2NR1H3PIK3CAABHD6DAGLA | |
| SCHEMBL13341021 | 0.85 | CKS1B (0.37) | CKS1BSKP1SKP2PARP1ABHD6 | |
| SCHEMBL13340982 | 0.80 | NR1H2 (0.44) | NR1H2NR1H3CKS1BSKP1SKP2 | |
| SCHEMBL3495634 | 0.76 | ALDH1A1 (0.34) | — | |
| SCHEMBL8237600 | 0.76 | ABHD6 (0.48) | NR1H2NR1H3PARP1ABHD6DAGLA | |
| SCHEMBL3495015 | 0.76 | NR1H2 (0.48) | NR1H2NR1H3 | |
| SCHEMBL3493284 | 0.75 | TP53 (0.34) | — | |
| SCHEMBL13705297 | 0.72 | APLNR (0.34) | NR1H2NR1H3PARP1KAT7ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | NR1H2 339/4885NR1H3 293/4885CKS1B 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.